RBC Capital analyst Simos Simeonidis said the positive NICE recommendation for Translarna is a positive that removes one of the major obstacles as the company proceeds with its EU launch, but he cautions that there is no correlation between the U.K.'s NICE and the broader EMA. What really matters for the stock is whether the EMA will decide to keep the drug in the EU market, which he believes is at serious risk. Simeonidis, who sees at least a 50% chance that Translarna get pulled from the EU market, keeps a Sector Perform rating and $9 price target on PTC shares.